Equity Overview
Price & Market Data
Price: $3.52
Daily Change: $0.00 / 0.00%
Daily Range: $3.24 - $3.67
Market Cap: $1,067,124,864
Daily Volume: 3,490,358
Performance Metrics
1 Week: 5.07%
1 Month: -3.03%
3 Months: 2.92%
6 Months: -40.94%
1 Year: 58.56%
YTD: 2.92%
Company Details
Employees: 562
Sector: Health technology
Industry: Biotechnology
Country: Canada
Details
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; and partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.